GORE VIABAHN FORTEGRA Venous Stent
W. L. Gore & Associates, Inc. · Decision date Apr 30, 2026
What did the FDA decide?
FDA records P250017/S003 as a supplement to PMA P250017, with the supplement type “30-Day Notice”. The recorded decision is OK30 (30-day notice), dated Apr 30, 2026.
FDA approval order statement
the addition of a second (internal) supplier for a trailing catheter subassembly
- Regulatory pathway
- PMA supplement
- Supplement type
- 30-Day Notice
- Clinical specialty
- Cardiovascular
- Decision date
- Apr 30, 2026
- FDA change category
- Process Change - Manufacturer/Sterilizer/Packager/Supplier
Regulatory record facts
- Identifier
- P250017/S003
- Regulatory pathway
- PMA supplement
- Applicant
- W. L. Gore & Associates, Inc.
- Product code
- QTL
- Decision code
- OK30
- Decision date
- Apr 30, 2026
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: Stent, vena cava.
- Applicant
- W. L. Gore & Associates, Inc.
- Product code
- QTL
- FDA device class
- 3
For the original device and its historical approval scope, see PMA P250017. Subsequent supplements may change the device or its indications.
FDA decision timeline
P250017 · Original PMA
GORE VIABAHN FORTEGRA Venous Stent
P250017/S002 · Related supplement
GORE VIABAHN FORTEGRA Venous Stent
P250017/S003 received
Application receipt date recorded by FDA.
P250017/S001 · Related supplement
GORE VIABAHN FORTEGRA Venous Stent
P250017/S003 · FDA decision
30-Day Notice
Timeline entries are records held by MedtechLedger for P250017. View FDA’s full supplement list.
Related devices and submissions
Same PMA: P250017
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
| W. L. Gore & Associates, Inc. | PMA approval | Dec 19, 2025 | FDA | |
GORE VIABAHN FORTEGRA Venous StentP250017/S002 | W. L. Gore & Associates, Inc. | PMA supplement | Mar 6, 2026 | FDA |
GORE VIABAHN FORTEGRA Venous StentP250017/S001 | W. L. Gore & Associates, Inc. | PMA supplement | Apr 7, 2026 | FDA |
Regulatory context
A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
W. L. Gore & Associates, Inc.
- Headquarters
- Not reported
- Brand website
- Not reported
- FDA applicant address
- 1505 N Fourth St., Flagstaff, AZ, 86004
Sources and methodology
- Original FDA record: P250017/S003
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 21, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records

